Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
TREAT TB
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
OTHER AREAS OF OUR WORK IN TUBERCULOSIS
You might also be interested in our work on child and adolescent TB and TB-HIV, TB-diabetes and co-morbidities.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
Learn more
Understand the issues with our fact sheets
DR-TB Union news
Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment
An article in a forthcoming issue of PHA assesses efforts to strengthen drug susceptibility testing in seven countries to support BPaL rollout, highlighting variable capacity and the need for ongoing training and infrastructure.
Financing the future of TB control: from dependence to resilience
An Editorial in a forthcoming issue of PHA highlights how cuts in donor funding for TB threaten progress but also present an opportunity for governments to invest in resilient, patient-centered health systems. The preprint is free to read.
Clean air for blue skies: protecting lungs, protecting lives
Today is the sixth International Day of Clean Air for Blue Skies, and we are reminded of the invisible crisis surrounding us: polluted…
Union members drive prioritisation of pregnant women
The recently published World Health Organization (WHO) call to action and consensus statement about prioritising pregnant and…